Rei Mimoto

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Clinical implications of drug-screening assay for recurrent metastatic hormone receptor-positive, human epidermal receptor 2-negative breast cancer using conditionally reprogrammed cells.

Clinical implications of drug-screening assay for recurrent metastatic hormone receptor-positive, human epidermal receptor 2-negative breast cancer using conditionally reprogrammed cells.

Journal: Scientific reports

Published: May 19, 2019

Long-Term Follow-Up of Node-Negative Breast Cancer Patients Evaluated via Sentinel Node Biopsy After Neoadjuvant Chemotherapy.

Long-Term Follow-Up of Node-Negative Breast Cancer Patients Evaluated via Sentinel Node Biopsy After Neoadjuvant Chemotherapy.

Journal: Clinical breast cancer

Published: April 10, 2017

Downregulation of dual-specificity tyrosine-regulated kinase 2 promotes tumor cell proliferation and invasion by enhancing cyclin-dependent kinase 14 expression in breast cancer.

Downregulation of dual-specificity tyrosine-regulated kinase 2 promotes tumor cell proliferation and invasion by enhancing cyclin-dependent kinase 14 expression in breast cancer.

Journal: Cancer science

Published: April 07, 2017

Dual-specificity tyrosine-regulated kinase 2 is a suppressor and potential prognostic marker for liver metastasis of colorectal cancer.

Dual-specificity tyrosine-regulated kinase 2 is a suppressor and potential prognostic marker for liver metastasis of colorectal cancer.

Journal: Cancer science

Published: December 21, 2016

Diminished DYRK2 sensitizes hormone receptor-positive breast cancer to everolimus by the escape from degrading mTOR.

Diminished DYRK2 sensitizes hormone receptor-positive breast cancer to everolimus by the escape from degrading mTOR.

Journal: Cancer letters

Published: July 11, 2016

Impairment of DYRK2 augments stem-like traits by promoting KLF4 expression in breast cancer.

Impairment of DYRK2 augments stem-like traits by promoting KLF4 expression in breast cancer.

Journal: Oncogene

Published: January 05, 2016

DYRK2 regulates epithelial-mesenchymal-transition and chemosensitivity through Snail degradation in ovarian serous adenocarcinoma.

DYRK2 regulates epithelial-mesenchymal-transition and chemosensitivity through Snail degradation in ovarian serous adenocarcinoma.

Journal: Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

Published: December 18, 2014

Clinical relevance and low tumor-initiating properties of oligometastatic breast cancer in pulmonary metastasectomy.

Clinical relevance and low tumor-initiating properties of oligometastatic breast cancer in pulmonary metastasectomy.

Journal: Breast cancer research and treatment

Published: July 22, 2014

Breast cancer screening and the changing population pyramid of Japan.

Breast cancer screening and the changing population pyramid of Japan.

Journal: Breast cancer (Tokyo, Japan)

Published: January 29, 2013

Individualized treatment of breast cancer chemotherapy

Individualized treatment of breast cancer chemotherapy

Journal: Nihon rinsho. Japanese journal of clinical medicine

Published: January 29, 2013

DYRK2 controls the epithelial-mesenchymal transition in breast cancer by degrading Snail.

DYRK2 controls the epithelial-mesenchymal transition in breast cancer by degrading Snail.

Journal: Cancer letters

Published: December 21, 2012

Showing 1-11 of 11

Last Updated: 09/26/2026